title: The complex interplay between cholesterol and prostate malignancy.
abstract: Research into the role of cholesterol and prostate disease has been ongoing for many years, but our mechanistic and translational understanding is still poor. Recent evidence indicates that cholesterol-lowering drugs reduce the risk of aggressive prostate cancer. This article reviews the literature on the relationship between circulating cholesterol and prostate cancer. The data strongly point to hypercholesterolemia as a risk factor for prostate cancer progression and suggest clinical opportunities for the use of cholesterol-lowering therapies to alter disease course.
authors.affiliation: The Urological Diseases Research Center, Children's Hospital Boston, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA. keith.solomon@childrens.harvard.edu
authors.forename: Keith R
authors.initials: KR
authors.lastname: Solomon
authors.forename: Michael R
authors.initials: MR
authors.lastname: Freeman
mesh_terms: D000728:Androgens / Q000096:biosynthesis; D002784:Cholesterol / Q000097:blood / Q000502:physiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy; D008297:Male; D017035:Pravastatin / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000209:etiology* / Q000378:metabolism; D012307:Risk Factors
chemical_list: D000728:Androgens; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol; D017430:Prostate-Specific Antigen; D017035:Pravastatin